Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ONCIN.OL
- Price
- 0.54
- Stock movement down
- -0.02 (-1.83%)
- Company name
- Oncoinvent ASA
- Exchange
- (OL ,
- Currency
- NOK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 115.14M
- Ent value
- 74.63M
- Price/Sales
- 43.25
- Price/Book
- 1.66
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -83.17%
- 3 year return
- -76.60%
- 5 year return
- -67.89%
- 10 year return
- -
Last updated: 2025-11-12
DIVIDENDS
ONCIN.OL does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 43.25 |
| Price to Book | 1.66 |
| EV to Sales | 28.04 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 97.74M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 75.39M |
| Net receivables | 1.05M |
| Total current assets | 81.81M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 20.50M |
| Total assets | 104.34M |
| Accounts payable | 7.08M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 31.39M |
| Total liabilities | 34.88M |
| Shareholder's equity | 69.46M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.20 |
| Daily high | 1.25 |
| Daily low | 1.18 |
| Daily Volume | 100K |
| All-time high | 586.68 |
| 1y analyst estimate | - |
| Beta | - |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 26 Feb 2026 |
Downside potential
Loading...
Downside potential data
| ONCIN.OL | S&P500 | |
| Current price drop from All-time high | -99.91% | -5.07% |
| Highest price drop | -99.82% | -19.00% |
| Date of highest drop | 17 Jul 2025 | 8 Apr 2025 |
| Avg drop from high | -63.15% | -2.73% |
| Avg time to new high | 120 days | 6 days |
| Max time to new high | 1873 days | 89 days |
COMPANY DETAILS
Marketcap
115.14M
Marketcap category
Small-cap
Description
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.
Employees
36
Website
Investor relations
-
SEC filings
CEO
Country
Norway
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced positive final 24-month follow-up results from its Phase 1 clinical tri...
October 8, 2025
Oncoinvent reports continued progress in the ongoing Phase 2 trial in ovarian cancer with a strong focus on advancing the program and maximizing recruitment.
August 27, 2025
BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time o...
June 30, 2025
BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger agreement (the "Agreement") to combine the two co...
June 30, 2025